0000904454-21-000413.txt : 20210416 0000904454-21-000413.hdr.sgml : 20210416 20210416115503 ACCESSION NUMBER: 0000904454-21-000413 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210415 FILED AS OF DATE: 20210416 DATE AS OF CHANGE: 20210416 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kuta Alexander Edward III CENTRAL INDEX KEY: 0001696698 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36294 FILM NUMBER: 21830590 MAIL ADDRESS: STREET 1: 239 WILLIS ROAD CITY: SUDBURY STATE: MA ZIP: 01776 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: uniQure N.V. CENTRAL INDEX KEY: 0001590560 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: PAASHEUVELWEG 25A CITY: AMSTERDAM STATE: P7 ZIP: 1105 BP BUSINESS PHONE: 1-339-970-7000 MAIL ADDRESS: STREET 1: PAASHEUVELWEG 25A CITY: AMSTERDAM STATE: P7 ZIP: 1105 BP FORMER COMPANY: FORMER CONFORMED NAME: uniQure B.V. DATE OF NAME CHANGE: 20131030 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2021-04-15 0001590560 uniQure N.V. QURE 0001696698 Kuta Alexander Edward III C/O UNIQURE N.V. PAASHEUVELWEG 25A AMSTERDAM P7 11058BP NETHERLANDS 0 1 0 0 Executive VP, Operations Ordinary Shares 2021-04-15 4 M 0 6000 5.31 A 74871 D Ordinary Shares 2021-04-15 4 S 0 6000 35.06 D 68871 D Stock Option (Right to Buy) 5.31 2021-04-15 4 M 0 6000 0 D 2027-01-23 Ordinary Shares 6000 92000 D The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The Stock Option vested 25% on January 23, 2018 (the first anniversary of the date of grant), and vests 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.64 to $35.46. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Christian Klemt, Attorney-in-Fact 2021-04-16